What to check before injecting a compounded GLP-1: the FDA's fraud red flags

• The FDA has confirmed fraudulent compounded semaglutide and tirzepatide with false pharmacy labels are circulating in the U.S.
• Some labels name pharmacies that don't exist. Others name real pharmacies that did not produce the product.
• Compounded drugs are not FDA-approved for safety, effectiveness, or quality — regardless of source.
• Two drugs — retatrutide and cagrilintide — cannot legally be used in compounding under federal law. Any product claiming to contain them is a serious red flag.
• If you have concerns about your current product, contact your pharmacy or prescriber. Do not stop your medication abruptly without talking to your clinician first.

The FDA's consumer alert page — "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" — states directly: the FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label.

In some cases, the compounding pharmacies listed on the labels do not exist. In others, the label names a licensed pharmacy that, based on information the FDA has gathered, did not actually compound the product.

The FDA has confirmed at least one adverse event report associated with a product labeled as compounded tirzepatide from a pharmacy that did not compound it. The reported symptoms included redness, site swelling, pain, and a lump at the injection site.

Separately, the FDA has received multiple reports of adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide. These involved patients measuring or self-administering incorrect doses, and in some cases, clinicians miscalculating doses.

The FDA has also issued warning letters to telehealth companies for making false and misleading claims about compounded GLP-1 drugs — including claims that compounded versions are "the same as" branded, FDA-approved drugs. That claim is not accurate. Compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.

The FDA's consumer alert page lists specific warning signs to watch for. Raise concern if a company or product:

• Claims the compounded drug is "the same as" an FDA-approved drug
• Offers medication at deep discounts or prices that seem implausibly low
• Sends medication that looks different than what you previously received, or that was pictured on the company's website
• Medication arrives in broken, damaged, or unlabeled packaging, or without instructions for use
• Does not require a prescription from a licensed doctor before dispensing
• Does not have a licensed clinician available to answer questions after you receive your medication
• Has spelling errors on the label, or lists an incorrect or unverifiable pharmacy address
• Includes a pharmacy name you cannot independently verify

That last point is the hardest to act on — but the section below explains how to check.

The FDA's BeSafeRx campaign (fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information) provides tools for verifying online pharmacies.

Check state licensing. Every legitimate compounding pharmacy must hold a current license from the state board of pharmacy where it is registered. Your state's board of pharmacy website allows you to look up active licenses by name. The National Association of Boards of Pharmacy (NABP) also maintains a verification directory at nabp.pharmacy.

Look for the NABP .pharmacy credential. The NABP awards a ".pharmacy" domain credential to pharmacies meeting its verification standards. This is not a quality guarantee but confirms basic legitimacy.

Confirm the pharmacy independently. A legitimate pharmacy will have a verifiable physical address and working phone number you can find through a public directory — not only through the telehealth platform that sold you the medication.

Ask your prescriber. A licensed clinician who prescribed your compound should be able to tell you where it is coming from and confirm whether the pharmacy is a 503A compounder (licensed under state law) or a 503B outsourcing facility (licensed under federal oversight with more stringent manufacturing standards).

The FDA's dosing error alert for compounded injectable semaglutide is a separate but related concern. Compounded injectable GLP-1s often come in multi-dose vials at concentrations different from branded auto-injector pens. Drawing the correct dose requires careful measurement — and errors have occurred.

If you are self-injecting a compounded GLP-1:

• Do not assume your dose volume is the same as what you'd see with a branded pen. Concentrations differ.
• Ask your pharmacy or prescriber for written instructions that specify your dose in the units printed on your syringe — not just a volume or percentage.
• If you are not certain how much to draw, contact your prescriber or pharmacist before injecting.

Injectable GLP-1 drugs require refrigeration, as stated in FDA-approved package inserts. The FDA has confirmed receiving complaints that certain compounded GLP-1 products arrived warm or with inadequate cold packing.

If your compounded GLP-1 arrives warm, or without adequate refrigeration, do not use it. Contact your pharmacy or prescriber. Improper temperature during shipping can affect a drug's integrity in ways that are not visible and cannot be assessed without laboratory testing.

The FDA's consumer alert explicitly states: retatrutide and cagrilintide cannot be used in compounding under federal law. Neither is a component of an FDA-approved drug, and neither has been found safe or effective through FDA review.

If a telehealth company or compounder is offering either drug in any form, that is a serious compliance red flag — they cannot legally provide it.

The full scale of fraudulent compounded GLP-1 products in circulation is not publicly quantified from the sources reviewed here. The FDA has confirmed the problem exists and is actively enforcing against it, but the agency's consumer alert does not provide a total count of confirmed fraudulent products.

The legitimate compounded GLP-1 landscape is also contracting. As the FDA removed semaglutide and tirzepatide from its drug shortage list in 2025–2026, many compounding pharmacies wound down or are winding down their GLP-1 programs. A pharmacy that was legitimately operating a year ago may no longer be authorized to compound these specific drugs. Verifying your pharmacy's current status — not just that it once existed — is worth doing before your next refill.

• Is this pharmacy currently licensed in my state, and can you provide the license number?
• Is this a 503A compounding pharmacy or a 503B outsourcing facility?
• Is this pharmacy still authorized to compound semaglutide or tirzepatide under current FDA guidelines?
• Can you provide instructions for use that specify my exact dose in the units on my syringe?
• What are your cold-chain shipping protocols, and what is your policy if a product arrives warm?

• Packaging and storage on arrival: are ice packs still cold? Is the product sealed and intact?
• Any unusual appearance: color, cloudiness, particulates, or inconsistency compared to previous vials
• Injection site reactions: redness, swelling, lumps, or pain beyond what you'd expect — document these and report to your prescriber
• Consider filing a MedWatch report (fda.gov/safety/medwatch) if you suspect a product quality problem
• Your pharmacy's current state license status — valid today may not mean valid at your next refill

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA consumer alert — concerns with unapproved GLP-1 drugs: fda.gov
• FDA April 2026 GLP-1 compounding clarification: fda.gov
• FDA BeSafeRx campaign: fda.gov